Antibody Drugs: Technologies and Global Markets

Oct 2017| BIO016K| BCC Publishing

Report Highlights

The global market for antibody drugs reached $80.8 billion in 2016. The market should reach $114.6 billion by 2022 increasing from $84.5 billion in 2017, at a compound annual growth rate (CAGR) of 6.3% from 2017 through 2022. 

Report Includes

  • An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
  • Analyses of global market trends, with data from 2014, 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
  • Analysis and assessment of the therapeutic applications of mAbs in human medicine.
  • A look at the antibody industry as a whole, as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
  • Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industries in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

Report Scope

This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.

BCC Research analyzes and makes projections for each market and its applications, the regulatory environment, new products and technological advances. Also included in the report are relevant patent analysis and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd. and Merck & Co.

The report covers the major markets of the U.S. and Europe, as well as emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.

Monoclonal antibodies are protein-based therapies/drugs that are finding use in the treatment of number of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.

The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human and humanized antibodies.

Excluded from this report are polyclonal antibodies; screening kits; and diagnostic uses of mAbs. Also excluded are research applications of mAbs and therapeutic antibodies for veterinary use.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Latest reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter Name Pages Price Member Price
Full Report: Antibody Drugs: Technologies and Global Markets 115 $2,750 Free
Chapter- 1: Introduction6Free
Chapter- 2: Summary and Highlights2$250Free
Chapter- 3: Market and Technology Background13$316Free
Chapter- 4: Market Breakdown by Technology Type24$584Free
Chapter- 5: Market Breakdown by Application23$560Free
Chapter- 6: Industry Structure7$170Free
Chapter- 7: Regulatory Aspects4$97Free
Chapter- 8: Patent Review/New Developments17$414Free
Chapter- 9: Analysis of Market Opportunities4$97Free
Chapter- 10: Company Profiles13$316Free
Chapter- 11: Appendix: Abbreviations2$49Free
Published - Jan-2015| Analyst - Shalini Shahani Dewan| Code - BIO016J

Report Highlights

The global market for antibody drugs was worth nearly $63.4 billion in 2013. This market is expected to grow at a compound annual growth rate (CAGR) of 12.2% between 2014 and 2019 resulting in totals nearly $68.9 billion in 2014 and $122.6 billion globally in 2019.

Report Includes

  • An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
  • Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.
  • Analysis and assessment of the therapeutic applications of mAbs in human medicine.
  • A look at the antibody industry as a whole as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
  • Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.
Published - Feb-2012| Analyst - Esther Bosklopper| Code - BIO016H

Report Highlights

The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011.  With the rollout of at least eight new therapeutic mAb products and expanded indications for existing products expected during the forecast period, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.

Published - Jan-2008| Analyst - Kim Lawson| Code - BIO016G

Report Highlights

This Report:

  • The global market for monoclonal therapeutic and diagnostic antibodies increased from $26 billion in 2006 to an estimated $31 billion by the end of 2007. It should reach $56 billion by 2012, a compound annual growth rate (CAGR) of 13%.
  • In 2007, the U.S. Food and Drug Administration approved 21 therapeutic monoclonal antibodies for therapeutic use under a drug approval review.
  • Monoclonal antibodies are a significant part of effective medical treatment and of financial deals within the biotechnology and pharmaceutical sectors of the economy.
Published - Aug-2005| Analyst - Lynn Gray| Code - BIO016F

Report Highlights

  • The worldwide market for therapeutic and diagnostic antibodies is estimated at $15 billion in 2005 and will rise at an average annual growth rate (AAGR) of 11.5% to nearly 26 billion in 2010.
  • Therapeutic antibodies dominate the market and are projected to have an AAGR of 11.4%, reaching $25.7 billion in 2010.
  • The therapeutic monoclonal antibody segment will rise at an AAGR of 12.4% while the therapeutic polyclonal market, driven more by volume and demand than innovation, is projected to see an AAGR of only 4%.
  • The diagnostic imaging market, though small, will experience an average annual growth near 17%, reaching $147 million in 2010.
Published - Oct-2002| Analyst - Lynn Gray| Code - BIO016E

Report Highlights

  • As of May 2002, there were 11 therapeutic monoclonal antibody products on the U.S. market. Worldwide, there were an estimated 470 monoclonal antibody products in development by more than 200 companies for the treatment of virtually every debilitating disease. Approximately 70 of these monoclonal antibody products were in clinical trials. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), monoclonal antibody products represented approximately 20% of all products in development and 33% of all biotech products in development by its members.
  • The therapeutic monoclonal antibody market is projected to have an average annual growth rate (AAGR) of approximately 25% throughout the forecast period. The therapeutic polyclonal antibody market, which is driven more by volume and demand than innovation, is projected to see an AAGR of just less than 11%. The diagnostic imaging market, though small, will see average annual growth exceeding 28% throughout the forecast period.

Published - Feb-2000| Analyst - Lynn Gray| Code - BIO016D

Report Highlights

  • Antibody-based drugs, in particular monoclonal antibody-based products, are on the brink of significant commercial growth. New developments are spurred in part by advances in technology that have now surmounted previous technical barriers to commercialization.
  • The information and analyses presented in this report on antibody-based drugs is an important asset in decision-making for managers involved in development, marketing, market research, product development, mergers and acquisitions, licensing, management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry.
  • The study provides a comprehensive analysis of the current markets for antibody drugs and, in particular, the market potential of promising drugs and technologies under development.

When do I get the report?
Most reports are fulfilled immediately. In some cases, it could take up to 24 hours.

In what format does this report get delivered to me?
We will send you an email with login credentials to access the report. You will also be able to download the pdf.

What are the free reports included in my purchase?
They consist of a collection of current reports from various partner publishers scanning multiple industries.

What is the difference between BCC Research and BCC Publishing?
BCC Research curates thousands of reports from different sources and provides access to this content to our clients. BCC Publishing is the publication arm of BCC Research (one of several publishers in our portal).

What reports do I get 'discounts' on with my purchase?
All reports. BCC Publishing reports will be available for a 50% discount. All other partner publishers are also available at deeply discounted rates.

Where are you located?
Wellesley Massachusetts, just outside of Boston, Massachusetts, USA.

How long has BCC Research been around?
We are approaching our 50 year anniversary in 2021!

What if I want you to invoice me for payment via Purchase Order?
Simply choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.

What if I have a question about your reports?
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times, and included in every purchase, to help our customers find the research they need-when they need it.

Can I share this report with my team?
Absolutely yes, with the purchase of additional user licenses.

Can I use your research in my presentation?
Absolutely yes, so long as the publisher is properly cited.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report